CRIS Current Research Information System

GUADAGNUOLO, VIVIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.895
EU - Europa 3.885
AS - Asia 2.100
AF - Africa 313
SA - Sud America 22
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
Totale 11.232
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.862
GB - Regno Unito 1.231
VN - Vietnam 835
SE - Svezia 692
CN - Cina 586
IT - Italia 513
DE - Germania 502
SG - Singapore 309
IN - India 221
IE - Irlanda 176
FR - Francia 160
RU - Federazione Russa 111
TG - Togo 110
EE - Estonia 92
ZA - Sudafrica 91
CH - Svizzera 85
UA - Ucraina 85
NG - Nigeria 61
BG - Bulgaria 59
BE - Belgio 46
CI - Costa d'Avorio 45
JO - Giordania 45
FI - Finlandia 43
GR - Grecia 39
CA - Canada 32
IR - Iran 27
JP - Giappone 15
BR - Brasile 13
NL - Olanda 12
PL - Polonia 8
UZ - Uzbekistan 8
EU - Europa 7
KR - Corea 7
LB - Libano 7
TR - Turchia 6
AT - Austria 5
AU - Australia 5
ES - Italia 5
ID - Indonesia 5
CL - Cile 4
CZ - Repubblica Ceca 4
PH - Filippine 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BD - Bangladesh 3
HK - Hong Kong 3
HR - Croazia 3
MK - Macedonia 3
PE - Perù 3
PT - Portogallo 3
SC - Seychelles 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
IL - Israele 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MA - Marocco 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
RO - Romania 2
SA - Arabia Saudita 2
TM - Turkmenistan 2
EG - Egitto 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
SI - Slovenia 1
TW - Taiwan 1
Totale 11.232
Salva come PNG Salva come JPEG
Città #
Southend 1.164
Dong Ket 660
Chandler 605
Fairfield 539
Ann Arbor 374
Ashburn 352
Houston 314
Wilmington 266
Woodbridge 265
Seattle 261
Singapore 253
Cambridge 204
Princeton 200
Dublin 175
Beijing 160
Bologna 117
Lomé 110
Westminster 101
Padova 94
Nanjing 93
Medford 86
Bern 75
New York 71
Abeokuta 61
Sofia 59
Santa Clara 53
Berlin 48
Bremen 46
Brussels 46
Abidjan 45
Amman 45
Saint Petersburg 45
Helsinki 43
Shenyang 42
Boardman 39
Nanchang 39
Redwood City 36
Redmond 35
Falls Church 34
Hebei 33
San Diego 33
Jinan 32
Florence 30
Changsha 27
Turin 27
Jiaxing 24
Toronto 21
Los Angeles 20
Milan 20
Mountain View 20
Norwalk 19
Tianjin 18
Zhengzhou 16
Hyderabad 14
Haikou 13
Hangzhou 13
Jacksonville 13
Paris 13
Ningbo 12
São Paulo 12
Bühl 10
Romainville 10
San Francisco 9
Athens 8
Grafing 8
Guangzhou 8
London 8
Olalla 8
Tokyo 8
Andover 7
Dearborn 7
Faenza 7
Kunming 7
Leawood 7
Rome 7
Taizhou 7
Zanjan 7
Fuzhou 6
Monmouth Junction 6
North York 6
Bareggio 5
Groningen 5
Jakarta 5
Kraków 5
Lanzhou 5
Napoli 5
Pune 5
Ulan-ude 5
Amsterdam 4
Busseto 4
Henderson 4
Istanbul 4
Phoenix 4
Sacramento 4
San Mateo 4
Taiyuan 4
Tappahannock 4
Washington 4
Augusta 3
Bitola 3
Totale 7.922
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 278
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 230
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 211
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 210
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 190
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 187
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 183
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 183
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 174
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 169
A case report of acute myeloid leukemia and neurofibromatosis 1 168
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 167
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 164
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 159
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 159
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 158
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 154
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 154
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 149
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 143
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 136
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 134
Clec12a: A new AML stem cell-associated antigen 131
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 131
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 128
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 126
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 125
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 125
null 123
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 122
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 122
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 121
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 119
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 119
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 119
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 118
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 118
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 118
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 117
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 117
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 117
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 117
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 116
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 115
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 114
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 114
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 114
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 113
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 113
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 112
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 110
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 110
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 110
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 106
SNP array reveals a new deletion of JAK2 in AML patients 105
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 103
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 102
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 101
You have accessEx-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 101
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 101
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 100
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 99
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 98
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 97
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 95
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 94
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 93
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 92
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 92
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 91
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 89
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 89
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 88
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 87
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 87
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 86
null 86
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 85
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 83
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 82
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 81
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 81
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 80
Gene expression signature of aneuploidy in acute myeloid leukemia 80
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 80
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 78
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 78
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 78
Molecular Characterization of PAX5 alterations in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) 78
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 78
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 78
null 77
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 74
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 70
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 69
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 69
Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study 68
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 63
Loss of the tumor suppressor genes CDKN2A/ARF impairs prognosis in adult BCR-ABL1 positive acute lymphoblastic leukemia (ALL) 51
IL-17/IL-10 double-producing T cells: New link between infections, immunosuppression and acute myeloid leukemia 30
Totale 11.507
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.978
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.978
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.184 0 0 5 168 265 237 309 305 392 199 191 113
2020/20211.982 270 117 52 35 56 87 39 117 151 86 83 889
2021/20222.175 188 54 115 185 252 142 58 117 130 155 399 380
2022/20232.493 318 392 106 356 180 196 78 117 392 55 181 122
2023/2024653 28 102 23 61 35 171 52 43 50 28 26 34
2024/2025514 91 360 63 0 0 0 0 0 0 0 0 0
Totale 11.544